Pancreatic Cancer Research

ResearcherNankai UniversityActive in the last 2 years

Guochao Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2801-2217; OpenAlex author ID A5102982186. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.72378↗
  2. First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metast… Co-author DOI 10.1038/s41392-025-02441-2↗
  3. Association of lung immune prognostic index with overall survival in pancreatic ductal adenocarcinoma patients treated using chemotherapy. First author DOI 10.7150/ijms.102404↗
  4. A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.017↗
  5. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer. First author DOI 10.1186/s12885-024-11823-8↗
  6. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma. First author DOI 10.3389/fonc.2022.926260↗
  7. Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. First author DOI 10.3389/fsurg.2022.1002075↗
  8. Identification of DNA methylation-driven genes and construction of a nomogram to predict overall survival in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-215080/v1↗
  9. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.12659/msm.927654↗
  10. The Correlation Analysis of Baseline Serum CA199, CEA and CA125 in Patients with Advanced Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-18126/v1↗
  11. Correlation Between Baseline Serum Tumor Markers and Clinical Characteristic Factors in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.2147/ott.s269720↗
  12. Preoperative CA19-9 levels predict disease-free survival and overall survival in pancreatic adenocarcinoma patients after resection. Co-author DOI 10.21037/tcr.2019.04.24↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guanghai Dai · 11 shared papers, 2019–2026 · strength 2.14
  2. Quanli Han · 5 shared papers, 2019–2025 · strength 0.93
  3. Mengjiao Fan · 3 shared papers, 2024–2026 · strength 0.69
  4. Yue Ma · 2 shared papers, 2024 · strength 0.50
  5. Ru Jia · 2 shared papers, 2024–2025 · strength 0.44
  6. Nan Zhang · 1 shared paper, 2025 · strength 0.33
  7. Shasha Guan · 2 shared papers, 2019–2022 · strength 0.26
  8. Mengjiao Fan · 1 shared paper, 2024 · strength 0.26
  9. Yue Ma · 1 shared paper, 2026 · strength 0.25
  10. Qian Zhou · 1 shared paper, 2022 · strength 0.22
  11. Guanghai Dai · 1 shared paper, 2025 · strength 0.20
  12. Hanzhi Cui · 1 shared paper, 2020 · strength 0.11
  13. Wen Zhang · 1 shared paper, 2020 · strength 0.11
  14. Jun Zhou · 1 shared paper, 2020 · strength 0.11
  15. Aiping Zhou · 1 shared paper, 2020 · strength 0.11
  16. Changjie Lou · 1 shared paper, 2020 · strength 0.11
  17. Yanqiao Zhang · 1 shared paper, 2020 · strength 0.11
  18. Yang Chen · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.